IMBRUVICA (ibrutinib) - Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure
New safety information - Product safety
Read the official notice →- Date
- 2022-08-29
- Country
- Canada
- Product
- IMBRUVICA (ibrutinib), 140 mg, 280 mg, 420 mg and 560 mg tablets, and 140 mg capsules
- Category
- Drugs & medical
- Source
- Health Canada
Copied automatically from the Government of Canada. Details may be shortened or out of date; the official notice is the authoritative source. Disclaimer
What to do
- Check the product name, strength and lot number against the official notice.
- Do not stop a prescribed medicine without talking to your doctor or pharmacist first.
- Ask the pharmacy or supplier about a replacement or refund.
General guidance from Recall Atlas. The official notice from the Government of Canada has the exact models, batch codes and remedy, and it takes priority.
Other drugs & medical recalls in Canada
- 2022-08-30
CADRAXIMAGE MDP: Affected lot may contain particulate matter
Product quality
Health CanadaOfficial notice →- 2022-08-29
- CA
NERFASIN 20: Affected lot may contain the presence of particles
Product quality
Health CanadaOfficial notice → - CA
JAMP ATORVASTATIN CALCIUM: Affected lot may be labelled with the incorrect strength on the label.
Dosage - Labelling
Health CanadaOfficial notice → - 2022-08-27
- CA
- 2022-08-25
- CA
- 2022-08-24
- CA